ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) COO Brian Dorsey sold 25,000 shares of the business's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $12.30, for a total transaction of $307,500.00. Following the completion of the sale, the chief operating officer now directly owns 6,024 shares in the company, valued at $74,095.20. This trade represents a 80.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
ARS Pharmaceuticals Stock Performance
Shares of NASDAQ:SPRY opened at $11.90 on Friday. ARS Pharmaceuticals, Inc. has a 52 week low of $5.02 and a 52 week high of $18.51. The company's fifty day moving average is $14.62 and its 200-day moving average is $12.34. The company has a market capitalization of $1.16 billion, a PE ratio of -23.33 and a beta of 0.88.
Wall Street Analyst Weigh In
SPRY has been the topic of several analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Leerink Partners boosted their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Friday, September 20th. Finally, William Blair raised shares of ARS Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $24.00.
This Crypto Is Set to Explode in December
From Crypto 101 Media | Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
View Our Latest Report on SPRY
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth about $30,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company's stock worth $63,000 after buying an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new position in ARS Pharmaceuticals during the 2nd quarter worth about $87,000. Quarry LP acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth about $174,000. Finally, TFG Advisers LLC acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth about $180,000. Institutional investors and hedge funds own 68.16% of the company's stock.
ARS Pharmaceuticals Company Profile
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
